Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles M Perou

Showing results (371-380 of 447) with videos related to

Pageof 45
Sort By:
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Journal of the National Cancer Institute|December 28, 2022
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, et al.
Breast Cancer Research and Treatment|July 9, 2014
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastasesCarey Anders, Allison M Deal, Vandana Abramson, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of RelapseAleix Prat, Ana Lluch, Arran K Turnbull, et al.
Science Signaling|March 27, 2014
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancerJessica J Tao, Pau Castel, Nina Radosevic-Robin, et al.
Nature|August 7, 2015
Corrigendum: Progesterone receptor modulates ERα action in breast cancerHisham Mohammed, I Alasdair Russell, Rory Stark, et al.
Ebiomedicine|January 6, 2022
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancerAleix Prat, Valentina Guarneri, Tomás Pascual, et al.
Cancer Research|May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristicsBryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.
Nature Communications|February 16, 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)Tomás Pascual, Maria Vidal, Juan M Cejalvo, et al.
Pageof 45

Showing results (371-380 of 447) with videos related to

Sort By:
Pageof 45
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Journal of the National Cancer Institute|December 28, 2022
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, et al.
Breast Cancer Research and Treatment|July 9, 2014
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastasesCarey Anders, Allison M Deal, Vandana Abramson, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of RelapseAleix Prat, Ana Lluch, Arran K Turnbull, et al.
Science Signaling|March 27, 2014
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancerJessica J Tao, Pau Castel, Nina Radosevic-Robin, et al.
Nature|August 7, 2015
Corrigendum: Progesterone receptor modulates ERα action in breast cancerHisham Mohammed, I Alasdair Russell, Rory Stark, et al.
Ebiomedicine|January 6, 2022
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancerAleix Prat, Valentina Guarneri, Tomás Pascual, et al.
Cancer Research|May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristicsBryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.
Nature Communications|February 16, 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)Tomás Pascual, Maria Vidal, Juan M Cejalvo, et al.
Pageof 45